Minapharm acquires ProBioGen for €30 million
This article was originally published in Scrip
Executive Summary
Minapharm Pharmaceuticals of Egypt has acquired 95% of the share capital of the privately held German firm ProBioGen for €30.4 million, which includes earn-out payments that are conditional on achieving certain milestones.
You may also be interested in...
Progress For Africa, As First Internal mAb Biosimilar Trialed In Europe
The quality of analytical data obtained so far and accepted by the German Federal Ministry of Health’s Paul-Ehrlich Institute has been praised as part of the step forward.
Who’s Hired? Stenico Takes Lead At Sandoz Germany
Sandoz has named Peter Stenico as permanent country head for its German operations. At the same time, Stada has appointed a trio of executives to key roles in Germany, Hovione has announced a new COO, Hikma and Orion have seen board changes and Sanofi’s biosimilars head in China has left the position for a new role.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.